Table 4.

Results from two proportional hazards models examining the influence of eGFR and albuminuria status, on likelihood of attaining systolic and diastolic blood pressure goals during follow-up

Covariate	Attainment of SBP goal			Attainment of DBP goal
	Hazard ratio	95% CI	p-value	Hazard ratio	95% CI	p-value
Age (years)	0.99	0.98–1.00	0.17	1.00	0.99–1.01	0.64
Male gender	0.71	0.54–0.95	0.020	0.77	0.58–1.03	0.07
African American race	1.02	0.67–1.55	0.91	1.06	0.69–1.63	0.80
Diabetes	0.83	0.62–1.12	0.23	1.31	0.96–1.78	0.09
BMI > 30 kg/m2	0.76	0.58–1.00	0.048	0.67	0.50–0.90	0.008
Therapeutic intensity score#	1.00	0.90–1.12	0.98	1.02	0.91–1.14	0.75
Difference from SBP or DBP goal at baseline	0.99	0.98–0.99	<0.001	0.97	0.96–0.98	<0.001
eGFR <60 ml/min/1.73 m2	0.74	0.54–1.02	0.07	0.85	0.61–1.18	0.32
Albuminuria status*:
Macro-albuminuria	0.54	0.35–0.83	0.005	0.87	0.56–1.36	0.54
Micro-albuminuria	0.71	0.53–0.97	0.032	0.82	0.60–1.13	0.23

Note: Model adjusted for visit month (time).

^*With normal albumin as reference. Normal = <30 mg/g creatinine; micro-albuminuria = 30–300 mg/g creatinine; macro-albuminuria = >300 mg/g creatinine.

^#Anti-hypertension therapeutic intensity score: calculated as daily dose/maximum FDA approved dose, summed across medication class.

Abbreviations: SBP, systolic blood pressure; DBP, diastolic blood pressure.